Atogepant is an oral medication used for the preventive treatment of migraine [1]. Its active ingredient is atogepant [1].
What is the mechanism of action for atogepant?
Atogepant functions as a calcitonin gene-related peptide (CGRP) receptor antagonist [1]. By blocking the CGRP receptor, it helps to prevent the vasodilation and neurogenic inflammation associated with migraine [1].
How is atogepant administered?
Atogepant is taken orally [1].
What are the approved uses for atogepant?
Atogepant is approved for the preventive treatment of episodic migraine in adults [1].
When does the patent for atogepant expire?
The patent expiry for atogepant can be tracked on DrugPatentWatch.com [2]. Information on patent status for pharmaceuticals is complex and subject to change [2].
Who manufactures atogepant?
AbbVie Inc. is the manufacturer of atogepant [1].
What are common side effects of atogepant?
Common side effects reported in clinical trials for atogepant include upper respiratory tract infection, nausea, and fatigue [1].
How does atogepant compare to other migraine prevention medications?
Atogepant is a CGRP receptor antagonist, a class of drugs that includes other oral medications like rimegepant and remogliflozin, as well as injectable CGRP antibodies [3]. Unlike the injectable CGRP antibodies which target the CGRP ligand, atogepant and other oral CGRP receptor antagonists target the receptor itself [3]. This offers an oral treatment option for migraine prevention [1].
Are there any contraindications for atogepant?
There are no listed contraindications for atogepant [1]. However, healthcare providers consider individual patient health profiles when prescribing medication.
What is the typical dosage of atogepant?
The recommended dosage for atogepant is 60 mg once daily [1].
What clinical trials have been conducted for atogepant?
Key clinical trials for atogepant include the ADVANCE trial for episodic migraine and the PROGRESS trial for chronic migraine [1]. These studies evaluated the efficacy and safety of atogepant in reducing monthly migraine days [1].
What are the risks associated with atogepant?
In clinical trials, atogepant was generally well-tolerated [1]. The most frequently reported adverse events were upper respiratory tract infection, nausea, and fatigue [1].
Can atogepant be used for acute migraine treatment?
Atogepant is indicated for migraine prevention, not for the acute treatment of migraine attacks [1].
What is the cost of atogepant?
The cost of atogepant can vary based on insurance coverage, pharmacy, and location. Patients are advised to check with their healthcare provider and insurance plans for specific pricing information.
Are there generic versions of atogepant available?
Currently, atogepant is available as a branded medication. The availability of generic versions will depend on patent expiries and regulatory approvals [2].
What are patient concerns regarding CGRP antagonists?
Patients may have questions about the long-term effects of CGRP antagonists, potential drug interactions, and whether these medications are suitable for all types of migraine [3]. Concerns also exist regarding the cost and accessibility of newer migraine treatments [3].
How does atogepant differ from triptans?
Triptans are typically used for the acute treatment of migraine attacks, whereas atogepant is used for migraine prevention [1][3]. Triptans work by constricting blood vessels and blocking pain pathways, while atogepant blocks the CGRP receptor to prevent migraine development [3].
What regulatory approvals does atogepant have?
Atogepant has received approval from regulatory bodies such as the U.S. Food and Drug Administration (FDA) for the preventive treatment of migraine [1].
What are the potential drug interactions with atogepant?
Atogepant is a substrate of CYP2D6, and co-administration with strong CYP2D6 inhibitors may increase exposure to atogepant [1]. Patients should discuss all medications they are taking with their healthcare provider [1].
What is the difference between atogepant and other oral CGRP antagonists?
While both atogepant and rimegepant are oral CGRP receptor antagonists, they may have different clinical profiles, including efficacy in specific migraine types and frequency of dosing [1][3]. Atogepant is specifically indicated for migraine prevention, while rimegepant is approved for both acute treatment and prevention of episodic migraine [1][3].
---
Sources:
[1] https://www.drugpatentwatch.com/atogepant
[2] https://www.drugpatentwatch.com/
[3] https://www.drugpatentwatch.com/blog/cgrp-inhibitors-for-migraine-treatment